Analysts expect pharma and healthcare companies to report a modest growth in Q3FY23, supported by healthy domestic market performance, tapering down of raw material and freight costs, and easing pricing pressures in the US coupled with a strong flu season. Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed (ARPOB) is likely to remain steady. In diagnostics, analysts model in high-single digit year-on-year (YoY) volume growth in core business, but margins are under pressure from competition.